Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 1.00 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 3/20 | 0.40 |
| ▸ | SRC | P12931 | 3/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721707 | 1.00 | PRKCI (1.00) | PRKCIBRPF1CYP2A6PIK3CBEGFR | |
| Hydrochloric Acid SCHEMBL7350283 | 0.98 | PRKCI (0.96) | PRKCIBRPF1CYP2A6PIK3CBEGFR | |
| SCHEMBL5718697 | 0.83 | PRKCI (0.70) | PRKCIBRPF1CYP2A6PIK3CBEGFR | |
| SCHEMBL29507010 | 0.83 | PRKCI (0.70) | PRKCIBRPF1CYP2A6PIK3CBEGFR | |
| SCHEMBL398452 | 0.83 | PRKCI (0.70) | PRKCIBRPF1CYP2A6PIK3CBEGFR | |
| Tert-Butyl Formate SCHEMBL28273704 | 0.82 | PRKCI (0.68) | PRKCIBRPF1CYP2A6PIK3CBEGFR | |
| Hydrochloric Acid SCHEMBL397061 | 0.81 | PRKCI (0.68) | PRKCIBRPF1CYP2A6PIK3CBEGFR | |
| SCHEMBL981889 | 0.80 | PRKCI (0.66) | PRKCICYP2A6PIK3CBEGFRHSD11B1 | |
| SCHEMBL18683804 | 0.76 | PRKCI (0.60) | PRKCIBRPF1CYP2A6PIK3CBHSD11B1 | |
| SCHEMBL29624271 | 0.76 | PRKCI (0.61) | PRKCICYP2A6PIK3CBHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416948-B1 | INDACENE BEARING SULFONYLUREAS AS ANTI-INFLAMMATORY AGENTS | UNIV QUEENSLAND (AU) | 2024-07-24 | — | — | EP | claimed |
| EP-4724443-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | Acrivon Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2024254490-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | ACRIVON THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2023-02-23 | — | — | US | disclosed |
| EP-3784662-B1 | COMPOUNDS HAVING A TUBULIN-POLYMERISATION-INHIBITING ACTIVITY AND IMMUNOMODULATORY PROPERTIES | UNIV PARIS SACLAY (FR) | 2022-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, MPST, CRAT | PRKCI 1376/4885BRPF1 3355/4885CYP2A6 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.